Related Experiment Video

Updated: Nov 23, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.3K

Selective inhibitory effects of HYIpro-3-1 on CYP1A2 in human liver microsomes

Younah Kim1, Ju-Hyun Kim2, Taeho Lee1

  • 1BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Republic of Korea.

Biopharmaceutics & Drug Disposition
|January 2, 2021
PubMed

Insights

HYIpro-3-1 selectively inhibits Cytochrome P450 1A2 (CYP1A2), a key enzyme in procarcinogen metabolism. This novel compound offers a potential strategy for cancer prevention by targeting CYP1A2 activity.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Toxicology

Background:

  • Cytochrome P450 1A2 (CYP1A2) is crucial for metabolizing xenobiotics and activating procarcinogens in the human liver.
  • Inhibiting CYP1A2 activity presents a potential therapeutic strategy for cancer prevention.
  • Understanding selective CYP1A2 inhibitors is vital for drug development and risk assessment.

Purpose of the Study:

  • To investigate the inhibitory effects of HYIpro-3-1 and its derivatives on CYP1A2 activity.
  • To characterize the inhibition mechanism and selectivity of HYIpro-3-1 against CYP1A2.
  • To evaluate HYIpro-3-1 as a potential selective CYP1A inhibitor.

Main Methods:

  • Utilized liquid chromatography-tandem mass spectrometry (LC-MS/MS) in a cocktail assay format.
  • Assessed inhibition in human liver microsomes (HLMs) and with purified human CYP1A2.
  • Determined IC50 and Ki values, and analyzed inhibition kinetics using Lineweaver-Burk plots.

Main Results:

  • HYIpro-3-1 demonstrated the most potent and selective inhibition of CYP1A2 among tested compounds.
  • Achieved an IC50 value of 0.1 µM in HLMs and a Ki value of 0.05 μM for competitive inhibition.
  • Inhibition by HYIpro-3-1 was found to be reversible and not dependent on preincubation time.

Conclusions:

  • HYIpro-3-1 is identified as a novel, selective, and potent inhibitor of CYP1A2.
  • The competitive and reversible inhibition mechanism suggests therapeutic potential for HYIpro-3-1.
  • HYIpro-3-1 warrants further investigation as a selective inhibitor of CYP1A activity in human liver microsomes.
Keywords:
CYP1A2HYIpro-3-1human liver microsomesinhibitor

More Related Videos

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.1K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.0K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
81
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
358
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
96
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
105
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
131
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
389